Drug firms engage more private docs

For years, drug firms sought out academic doctors to discuss new products via sponsored talks.

Now, due to tighter ethics policies adopted by many leading universities, that trend may be changing, reports the Milwaukee Journal Sentinel.

The growing number of university conflict-of-interest policies have “forced [industry] to back away from” engaging faculty, noted the Journal Sentinel, and that's dangerous as there is no way to control their participation in the same way that medical schools can restrict biased talks or require speakers to disclose industry ties.

The paper profiled one private Wisconsin physician who received $45,000 from GlaxoSmithKline during a three-month period in 2009, and another who got $61,000 for talks given during the first nine months on behalf of Eli Lilly.  Neither was able to prove that they disclose financial relationships every time.

GSK told the paper that its speaker program has been affected by conflict-of-interest restrictions but that it does not seek private doctors over others.

The article did not analyze the number of physicians listed by GSK and the other companies that have disclosed payments to doctors for parts or all of 2009—Merck, Lilly and Cephalon—and how many are in private practice vs. on faculty.

In recent years, Harvard, Stanford, Duke and other schools have restricted paid speaking.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.